MacuLogix® Enters Canadian Distribution Agreement With Clarion Medical Technologies

Clarion will add AdaptDx® to its portfolio of advanced ophthalmic technologies

MIDDLETOWN, Pa., Oct. 23, 2018 /PRNewswire/ -- MacuLogix, Inc., the only company to equip eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with AMD, has entered into an international distribution agreement with Clarion Medical Technologies, a leading Canadian provider of medical and aesthetic equipment and consumables. Effective immediately, Clarion will add the AdaptDx automated dark adaptometer to its Vision division's portfolio of products.

"We are very pleased to partner with Clarion to expand our reach into Canada," said Armond Dantino, Vice President of Sales for MacuLogix. "Bringing the AdaptDx to Canada is critical to preserving vision, as AMD accounts for 90 percent of new cases of legal blindness in Canada according to the Canadian Ophthalmological Society."

"The AdaptDx is an exciting addition to Clarion's expansive portfolio of revolutionary ophthalmic devices, lenses and nutraceuticals," commented Dan Webb, Chairman of Clarion Medical Technologies. "We take great pride in offering cutting-edge technology solutions to our Vision customers and are confident that Canadian eye care professionals will find great value in the AdaptDx for detecting and monitoring age-related macular degeneration."

AMD has been identified as the leading cause of adult blindness in developed countries because diagnosing AMD at the earliest stages has been a challenge. The AdaptDx is the first commercially available dark adaptometer that can be used in clinical practice to detect AMD at a subclinical stage, before structural changes in the retina like drusen become visible. Patients are often asymptomatic, have good corrected visual acuity, and their retina appears normal upon clinical evaluation. Thankfully, research has shown that functional assessment of dark adaptation using the AdaptDx can radically improve diagnostic sensitivity and specificity by detecting the disease with 90 percent accuracy at least three years before structural changes such as drusen are visible, enabling clinicians to intervene before irreversible vision loss occurs.

About MacuLogix®
MacuLogix, Inc. equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx®, MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. MacuLogix provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx. 

About Clarion Medical Technologies Inc.
Clarion Medical Technologies is one of Canada's largest private medical companies. Since 1989, Clarion has focused on delivering innovative solutions for Vision, Urology, Gynecology, ENT and Aesthetic markets by sourcing high performance, best in class products. By harnessing innovative technologies, the talents of their people and the expertise of their partners, Clarion delivers advanced solutions that help improve the quality of healthcare. Their products and services include laser technologies, diagnostic equipment, skincare, dermal fillers, intra-ocular lenses, laser fibers, clinical education, laser safety, and technical support.  

Contact MacuLogix:
Amy Hellem
[email protected]
(610) 304-6746

Contact Clarion:
Colleen Shambrook
[email protected]
(519) 620-3900 x 1258

SOURCE MacuLogix, Inc.